Back to Browse Journals » Vascular Health and Risk Management » Volume 5

Prognostic stratification of acute pulmonary embolism: Focus on clinical aspects, imaging, and biomarkers

Authors Luca Masotti, Marc Righini, Nicolas Vuilleumier, Fabio Antonelli, et al.

Published 2 July 2009 Volume 2009:5 Pages 567—575

DOI https://doi.org/10.2147/VHRM.S4861

Review by Single-blind

Peer reviewer comments 3

Luca Masotti1, Marc Righini2, Nicolas Vuilleumier3, Fabio Antonelli4, Giancarlo Landini5, Roberto Cappelli6, Patrick Ray7

1Internal Medicine, 4Clinical Chemistry, Cecina Hospital, Cecina, Italy; 2Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital, Switzerland; 3Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals and University of Geneva, Switzerland; 5Internal Medicine, Santa Maria Nuova Hospital, Florence, Italy; 6Thrombosis Center, University of Siena, Siena, Italy; 7Department of Emergency Medicine, Centre Hospitalo-Universitaire Pitié-Salpêtrière, UPMC Paris 6, Paris, France

Abstract: Pulmonary embolism (PE) represents a common disease in emergency medicine and guidelines for diagnosis and treatment have had wide diffusion. However, PE morbidity and mortality remain high, especially when associated to hemodynamic instability or right ventricular dysfunction. Prognostic stratification to identify high risk patients needing to receive more aggressive pharmacological and closer monitoring is of utmost importance. Modern guidelines for management of acute PE are based on risk stratification using either clinical, radiological, or laboratory findings. This article reviews the modern treatment of acute PE, which is customized upon patient prognosis. Accordingly the current risk stratification tools described in the literature such as clinical scores, echocardiography, helical computer tomography, and biomarkers will be reviewed.

Keywords: pulmonary embolism, prognosis, troponin, BNP, NT-proBNP, echocardiography, computer tomography

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Pulmonary embolism in the elderly: a review on clinical, instrumental and laboratory presentation

Luca Masotti, Patrick Ray, Marc Righini, Gregoire Le Gal, Fabio Antonelli, et al

Vascular Health and Risk Management 2008, 4:629-636

Published Date: 6 June 2008

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Advances in cancer pain from bone metastasis

Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY

Drug Design, Development and Therapy 2015, 9:4239-4245

Published Date: 18 August 2015

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

ElHalawani H, Abdel-Rahman O

Therapeutics and Clinical Risk Management 2015, 11:1123-1132

Published Date: 28 July 2015

Clinical utilities of aromatase inhibitors in breast cancer

Chumsri S

International Journal of Women's Health 2015, 7:493-499

Published Date: 6 May 2015

Colorectal cancer in Chinese patients: current and emerging treatment options

Li L, Ma BBY

OncoTargets and Therapy 2014, 7:1817-1828

Published Date: 4 October 2014

Breast cancer causes and treatment: where are we going wrong?

Seymour CB, Mothersill C

Breast Cancer: Targets and Therapy 2013, 5:111-119

Published Date: 3 December 2013

Update of research on the role of EZH2 in cancer progression

Shen L, Cui J, Liang S, Pang Y, Liu P

OncoTargets and Therapy 2013, 6:321-324

Published Date: 4 April 2013

Implications for breast cancer dormancy in other areas of medicine

Rameshwar P

Breast Cancer: Targets and Therapy 2012, 4:193-195

Published Date: 5 December 2012

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Yee AJ, Raje NS

Clinical Interventions in Aging 2012, 7:331-338

Published Date: 3 September 2012

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011